-
Uncategorized2 months agoSTAT+: An insider reveals the real goals of prior authorization
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. Well, it appears the Associated Press chose violence with this grammar...
-
Uncategorized2 months ago
Sun Pharma beams up Organon in $11.75B acquisition
Sun Pharmaceutical is bringing Merck spinoff Organon into the fold, paying $11.75 billion in hopes of becoming a top global biosimilar player.
-
Uncategorized2 months ago
Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi
Oruka Therapeutics’ Phase 2 psoriasis data could mean there’s a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%)...
-
Uncategorized2 months ago
Genetic Medicine Delivery Enhanced by Producer Cell Modifications
Gene editing has emerged as a powerful approach for targeting the genetic causes of disease, yet delivering the editing machinery into the correct cells efficiently, safely, and at the scale needed for therapies remains one of...
-
Uncategorized2 months agoSTAT+: Astellas retries XLMTM gene therapy after deaths
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. New hair loss data for...
-
Uncategorized2 months ago
Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax
Eli Lilly is picking up Ajax Therapeutics and its once-daily oral blood cancer candidate. The deal follows the pharma’s buyouts of ADC specialist CrossBridge Bio and...
-
Uncategorized2 months ago
Intellia heads to FDA after notching first late-stage win for in vivo gene editor
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for hereditary angioedema.
-
Uncategorized2 months ago
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying...
-
Uncategorized2 months ago
UCSF, Par Health hit with FDA warning letters for environmental monitoring issues
UCSF, Par Health hit with FDA warning letters for environmental monitoring issues
-
Uncategorized2 months ago
Seaport, Hemab chart courses for $180M IPOs to fund depression, clotting candidates
Both Seaport and Hemab are hoping to bring in around $180 million each from their public listings this week, in the latest sign that biotech IPOs...
